### JC05 Rec'd PCT/PTO 03 OCT 2005

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Cosford, et al.		10/552362
Filed: For: DI-ARY OF ME	to be assigned  YLSUBSTITUTED TRIAZOLE MODULATORS TABOTROPIC GLUTAMATE RECEPTOR-5	Art Unit: Examiner: _	·
Commissioner		•	

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

## INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

Sir:

- 1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application. This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention. In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).
- 2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.
- 3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.
- 4. Pursuant to 37 C.F.R. 1.98 (a)(2)(ii), copies of each cited U.S. patent and each U.S. patent application publication are not enclosed herewith.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

MERCK & CO., INC.

By \_\_\_\_\_ Date \_\_\_\_\_

# JC05 Rec'd PCT/PTO 03 OCT 2005 PATENT Case No. MS0036YF

**FILING DATE** 

**RELATED APPLICATION** 

**MERCK CASE** 

## INFORMATION DISCLOSURE STATEMENT 10/552362

5. Pursuant to 37 C.F.R. 1.98(d), copies of references listed on the attached form that were submitted to or cited by the Office in a related application upon which the instant application relies for an earlier filing date under 35 U.S.C. 120 are not enclosed. Related application(s) in which references were submitted to or cited by the Office are as follows:

U. S. SERIAL NUMBER

	1	
If this is inconvenient, additional copies will be submitted upon reques	st.	
6. In accordance with 37 C.F.R. 1.97, (check one)		
the attached information is filed within three months of the filing da	ate of the captioned case.	
the attached information is filed more than three months after the Office Action on the merits.	filing date but prior to the m	ailing of a first
the attached information is filed before the mailing of a first Office examination under §1.114.	action after the filing of a re	quest for continued
the attached information is being filed more than three months after Office Action on the merits, but before the mailing date of a Final Action of the office Action in the application. The enclosed authorized authorized the count No. 13-2755 for the fee required under 37 C.F.R. 1.17(p)	Action, Notice of Allowance thorization is therefore give	, or an action that
each item of information contained in this Information Disclosure S from a foreign patent office in a counterpart foreign application no Statement.		
each item of information contained in the information disclosure so from a foreign patent office in a counterpart application and this condesignated in §1.56(c) more than thirty days prior to the filing of the	ommunication was not rece	ived by any individual
no item of information contained in this Information Disclosure State foreign patent office in a counterpart foreign application, and, to the after making reasonable inquiry, was known to any individual designments prior to the filing of this Statement.	e knowledge of the person	signing the certification
	Respectfully submitted,	_

By: David A. Rubin

Attorney For Applicant(s)

Reg. No. 40,314

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594-<u>2675</u>

Date: October 3, 2005

SUBSTITUTE for PTO/SB/08A (07-05), Information Disclosure Statement by Approach

* Substitute or form 1449A/PTO				COMPLETE IF KNOWN			
INFORMATION DISCLOSURE		Application Number	181550719				
		Filing Date	10/552362				
5	STATEMENT BY APPLICANT			First Named Inventor			
				Group Art Unit			
	(use as many sheets	as n	ecessary)	Examiner Name			
Sheet	1	of	2	Attorney Docket Number	MS0036YP		

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.	U.S. Patent Document	Kind Code (known)		Date of Publication of Cited Document MM-DD-YYYY	
					05/30/2000	
			<u> </u>			
			1			
			1			

	FOREIGN PATENT DOCUMENTS							
Foreign Patent Document				Date of Publication of				
Examiner Initials*	Cite No.	Office	e Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY		
	Al		WO 03/051315 A2		Cosford, et al.	06/26/2003		
						Λ.		

Examiner Signature Date Considered			
	Signature	Considered	

Substitute for form 1449B/PTO INFORMATION DISCLOSURE		Application NaCO5 Rec'd PCT/PTO 03 OCT 2005			
S	TATEMENT BY	A D	DITCANT	Filing Date	10/552362
3	IAIEMENI DI	АГ	FLICANI	First Named Inventor	
	(			Group Art Unit	
	(use as many sheets	as n	ecessary)	Examiner Name	·
Sheet	2	of	2	Attorney Docket Number	MS0036YP

	NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.		
	A2	Revesz. et al., SAR of 2,6-Diamino-3,5-difluoropyridinyl Substituted Heterocycles as Novel p38 MAP Kinase Inhibitors, Bioorganic & Medicinal Chemistry Letters, 12 (2002) 2109-2112.		
	,			

a: 1 a	Date Considered
--------	--------------------

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.